← All trials
NCT06398652
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 27, 2024
- Primary completion
- May 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- May 3, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 336
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taizhou Mabtech Pharmaceutical Co., Ltd.Lead sponsor
- Fudan UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.